Business
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026Spero maintains its cash runway guidance into 2028 CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial
About this update from Spero Therapeutics, Inc.
[{"type":"image","alt":"Spero Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Spero Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/6fe4b8bd1b5673c609e8e3cb8c688861"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NZ7Kj4X.syHvrTwbJDWHqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6fe4b8bd1b5673c609e8e3cb8c688861","width":300,"height":108},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/NZ7Kj4X.syHvrTwbJDWHqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6fe4b8bd1b5673c609e8e3cb8c688861","width":300,"height":108}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026","length":180,"tagName":"p"}]},{"val":[{"type":"text","content":"Spero maintains its cash runway guidance into 2028 ","length":50,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":230,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.","length":352,"tagName":"p"},{"type":"text","content":"“We continue to make solid progress on the tebipenem HBr program alongside our licensing partner, GSK, as we prepare for the FDA’s decision expected in June,” said Esther Rajavelu, President and CEO of Spero Therapeutics. “With GSK's leadership in anti-infectives, tebipenem HBr, if approved, has the potential to meaningfully improve treatment options for cUTI patients. Looking ahead, we are positioning the company for the next phase by advancing other corporate activities, including exploring opportunities to grow our portfolio of clinical-stage product candidates.”","length":576,"tagName":"p"},{"type":"text","content":"Program Update","length":14,"tagName":"p"},{"type":"text","content":"Tebipenem HBr","length":13,"tagName":...